Investigational Drug Information for ASTX660
✉ Email this page to a colleague
What is the development status for investigational drug ASTX660?
ASTX660 is an investigational drug.
There have been 11 clinical trials for ASTX660.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 31st 2025.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are Astex Pharmaceuticals, Inc., National Cancer Institute (NCI), and Astex Pharmaceuticals.
There are fifty-four US patents protecting this investigational drug and one hundred and eighty-five international patents.
Summary for ASTX660
| US Patents | 54 |
| International Patents | 185 |
| US Patent Applications | 147 |
| WIPO Patent Applications | 51 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 1 (2025-10-31) |
| Vendors | 41 |
Recent Clinical Trials for ASTX660
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | National Cancer Institute (NCI) | PHASE1 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer | National Cancer Institute (NCI) | PHASE1 |
| Preoperative Radiotherapy And ASTX660 in Rectum Cancer | Gustave Roussy, Cancer Campus, Grand Paris | PHASE1 |
Clinical Trial Summary for ASTX660
Top disease conditions for ASTX660
Top clinical trial sponsors for ASTX660
US Patents for ASTX660
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASTX660 | ⤷ Start Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Start Trial |
| ASTX660 | ⤷ Start Trial | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP) | ⤷ Start Trial |
| ASTX660 | ⤷ Start Trial | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (Cambridge, GB) | ⤷ Start Trial |
| ASTX660 | ⤷ Start Trial | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Start Trial |
| ASTX660 | ⤷ Start Trial | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASTX660
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASTX660 | Argentina | AR107001 | 2035-12-17 | ⤷ Start Trial |
| ASTX660 | Australia | AU2016370916 | 2035-12-17 | ⤷ Start Trial |
| ASTX660 | Brazil | BR112017002594 | 2035-12-17 | ⤷ Start Trial |
| ASTX660 | Canada | CA2951911 | 2035-12-17 | ⤷ Start Trial |
| ASTX660 | Canada | CA3006772 | 2035-12-17 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
